Home  |  Journals  |  Conferences |   Membership  |   FAQ's Join  |  Contact  |   Sitemap  |             

International Journal of Clinical & Medical Images

ISSN: 2376-0249
Open Access
 
 
 

Evolution Of Invasive Aspergillosis In Hematopoietic Stem Cell Transplantation

Other Art Works

Image 01 Image 02
Image 03 Image 04
Image 05 Image 06
Image 07 Image 08
Image 09 Image 10
Image 11 Image 12
Image 13 Image 14
Image 15 Image 16
Image 17 Image 18
Image 19 Image 20
Image 21 Image 22
Image 23 Image 24
Image 25 Image 26
Image 27 Image 28
Image 29 Image 30

Abstract
Invasive aspergillosis is still a major complication of allogeneic Hematopoietic Stem Cell Transplantation (HSCT). We describe a case of extensive fungal pneumonia due to Aspergillus spp successfully treated with a combination of antifungal agents and surgery.
Keywords: Aspergillosis; HSCT; Pneumonectomy
In November 2012, a 66-year-old caucasian male underwent an un-manipulated Hematopoietic Stem Cell Transplantation (HSCT) from his haploidentical daughter for a secondary Acute Myeloid Leukemia (AML) in relapse. Because of a single pulmonary nodule (Figure 1A) present before transplant, the patient received Voriconazole as secondary prophylaxis through the transplant. During post-transplantation aplasia, he developed a severe pneumonia with respiratory distress requiring non invasive ventilation support. A chest CT scan (Figure 1B) showed a massive lobar pneumonia with ground glass opacity; a bronchoalveolar lavage was diagnostic for septate hyphae suggestive for Aspergillus and panfungal PCR-assay was concomitantly positive. The patient added liposomal Amphotericin B to Voriconazole; after few days neutrophils engrafted. First bone marrow evaluation(Figure 1C) showed a consolidation with cavitation of the major lesion. The patient was discharged after two months of combination therapy, on Posaconazole. At six months from HSCT, in continuous AML complete remission, the patient was brought in the operating theatre for left pneumonectomy. The patient is actually alive, in complete remission, with no respiratory distress and normal pulse oximetry in room air, at 18 months from HSCT (Figure 1D).

 

*Corresponding author: Peccatori Jacopo, Hematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, Milano, Italy, E-Mail: peccatori.jacopo@hsr.it

 
 
© 2008-2013 OMICS Group - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version